...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Breakthrough Therapy Designation Application

Also keep in mind that there hasn't been a peep about the CKD sub-study results yet. All we've heard is about the MACE benefit in this group; however, that was not the focus of the CKD sub-study. We need the renal data!

https://www.resverlogix.com/upload/media_element/125/20402f6425eb/2018-05-02-era-edta-poster-2018-kidney-disease-subgroup.pdf

 

Share
New Message
Please login to post a reply